| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-06 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.16 | 3e-06 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.18 | 9e-05 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0004 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0005 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.18 | 0.0007 |
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.001 |